Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine Combined with Escitalopram in Major Depressive Disorder
NCT03131050Phase 4Completed
- Sponsor
- Capital Medical University
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of scopolamine in major depressive disorder (MDD) (3 arms), sponsored by Capital Medical University. Primary endpoint: Time from randomization to early improvement at 4 weeks. Started Mar 2017; status: completed.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03131050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131050.